Financings

SANTA CLARA, Calif. – It has never been easy to get payers to reimburse in a timely and adequate fashion for novel diagnostics, making it notoriously difficult to build a business from them. But a few high-flying diagnostics companies, such as Madison, Wis.-based Exact Sciences Corp. and Redwood City, Calif.-based Guardant Health Inc., have been blazing the trail recently on how to rapidly scale up to become valuable commercial entities from origins as a research-based startup.

Ionctura closes series A for next-generation dual-targeting cancer therapies

January 23, 2020

By Nuala Moran

No Comments

LONDON – Ionctura SA has closed a €15 million (US$16.6 million) series A to fund phase I development of its lead cancer program, IOA-244, and prepare a second product, IOA-289, for clinical development.

Financings for Jan. 23, 2020

January 23, 2020

No Comments

Biopharmas raising money in public or private financings, including: Autolus, Blueprint Medicines, Chi-Med, Genprex, Karuna, Immunogen, Puretech Health, Seneca, Tetraphase, Trillium, Vitro Diagnostics, Xenon, Zymeworks

Financings for Jan. 22, 2020

January 22, 2020

No Comments

Med-tech firms raising money in public or private financings, including: Aethlon Medical, Profound Medical, Sequana Medical

Born again: Neurotrope back in the game with bryostatin-1 in Alzheimer’s

January 22, 2020

By Lee Landenberger

No Comments

It was a trifecta to remember for Neurotrope Inc. on Wednesday as the company cast revealing light on a seemingly failed clinical program involving its lead candidate, had the NIH offer a grant to create a phase II trial to explore the program’s strengths, and then found institutional investors and individuals to pony up an $18 million registered direct offering for the company’s securities. It was a re-examination of data that resurrected Neurotrope’s hopes for its lead candidate months after a confirmatory phase II of bryostatin-1 failed to outperform a placebo in people with moderately severe to severe Alzheimer’s disease (AD) in the absence of Namenda (memantine, Allergan plc), an NMDA receptor antagonist.

Investors bankroll 3D microfluidic tissue printing platform

January 22, 2020

By David Godkin

No Comments

TORONTO – Vancouver, British Columbia-based Aspect Biosystems Inc. has raised CA$26 million (US$20 million) in series A funding to help develop 3D bioprinter technology that uses the science of microfluidics to create fresh human tissue.

PDC*Line Pharma pulls in $22M in equity, grants for lung cancer immunotherapy

January 22, 2020

By Cormac Sheridan

No Comments

PDC*Line Pharma SA raised €13.9 million (US$15.4 million) in a series B round plus another €6.1 million in loans and grants from the Walloon region of Belgium to take its allogeneic cell-based cancer immunotherapy, PDC*lung-01, into a phase I/II trial in patients with metastatic lung cancer.